Tempest Q1 net loss $10.9M; cash $21.5M; exploring strategic alternatives

Tempest Therapeutics, Inc.

2025-Q1 EPS reported -$3.16

Cash and equivalents $21.5M at March 31, 2025, down from $30.3M at Dec 31, 2024.
Net loss $10.9M ($3.16/share) vs $7.9M ($4.62/share) in Q1 2024; R&D expense $7.6M.
Completed workforce reduction on April 30, 2025; repaid $3.5M loan to Oxford Finance.
FDA granted Orphan Drug and Fast Track designations for amezalpat in HCC.
TPST-1495 granted Orphan Drug for FAP; FDA allowed Phase 2 trial to proceed.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0000950170-25-070416
form_type: 8-K
ticker: TPST
cik: 0001544227
company_name: Tempest Therapeutics, Inc.
filed_at: 2025-05-13T23:59:59+00:00
discovered_at: 2026-05-14T18:02:48.711760+00:00
generated_at: 2026-05-21T15:35:46.745981+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0000950170-25-070416
json_url: https://secwatch.observer/filing/0000950170-25-070416.json
markdown_url: https://secwatch.observer/filing/0000950170-25-070416.md
text_url: https://secwatch.observer/filing/0000950170-25-070416.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1544227/000095017025070416/0000950170-25-070416-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1544227/000095017025070416/tpst-20250513.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0000950170-25-070416

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.